Solvonis (LSE: SVNS, OTC: SLVNF) is a small-cap UK clinical-stage biotech focused on developing novel treatments for addiction and mental health disorders, specifically Alcohol Use Disorder (AUD) and PTSD. I strongly believe in treatments such as these to help treat the root cause of the issue, rather than trying to manage the symptoms which lead to so many deaths every year.
Trump's recent executive order to accelerate the research and approval for these types of drugs (psychadelics) is a significant validator for the US market. The current market cap of £16m is significantly undervalued compared with Solvonis' US peers with similar drug technology which are valued in the $billions. I believe this is because the UK has a severe lack of institutional and government funding for small-cap biotechs. I can strongly recommend listening to a recent interview with the CEO of Solvonis.
[https://youtu.be/pbHZmEyh7Fk?t=2858](https://youtu.be/pbHZmEyh7Fk?t=2858)
Two near-term events could violently re-rate the share price, currently at 0.24p, pushing up to an average 12-month target of 1.7p (600% upside).
* **WuXi AppTec Part 2 Data:**
* **Timing:** Expected in the **near term** (mid-2026).
* **Impact:** This technical data is viewed as a major catalyst to validate the company's R&D platform.
* **Water Tower Research Launch:**
* **Timing:** Ongoing/Expected **Q2–Q3 2026**.
* **Impact:** Designed to increase visibility and promotion within the **U.S. market**, targeting American institutional investors and decision-makers in the neuropsychiatric space.
